Find Clinical Trials

Brain    Breast    Cancer Control    Gastrointestinal    Genitourinary    Gynecology    Head and Neck    Hematology    Lung    Melanoma    MNCCTN    Sarcoma    Other

Brain

November 11, 2025 in Brain

A072201: Randomized Phase II Trial of Anti-LAG-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma (NCT06325683)

Read More
May 12, 2025 in Brain

BN013: Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases (NCT06500455)

Read More
November 29, 2022 in Brain

BN012

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases (NCT05438212)
Read More
September 14, 2022 in Brain

A071401

PHASE II TRIAL OF SMO/AKT/NF2/CDK INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2/CDK PATHWAY MUTATIONS
Read More
June 30, 2022 in Brain

CE.7

A phase III trial of stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for 5-15 brain metastases.
Read More
June 30, 2022 in Brain

BN011

BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma (NCT 05095376)
Read More
See All

Breast

June 3, 2025 in Breast

A012301: LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

Read More
May 6, 2025 in Breast

DCIS: RECAST (Open at HCMC Only)

DCIS: RECAST Trial – Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a breast cancer prevention pilot study
Read More
April 7, 2025 in Breast

ELEGANT/STML-ELA-0422

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Read More
September 30, 2024 in Breast

CAMBRIA-2/AFT-66

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or…
Read More
June 27, 2024 in Breast

B-64/EXActDNA-003

EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease…
Read More
June 12, 2024 in Breast

OPERA-01

A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK 4/6 INHIBITOR…
Read More
See All

Cancer Control / Cancer Care Delivery Research (CCDR)

November 10, 2025 in Cancer Control / CCDR

U24060: Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

Read More
September 24, 2025 in Cancer Control / CCDR

S2417CD: A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention Called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance

Read More
February 12, 2025 in Cancer Control / CCDR

WF2304/COSMIC: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (NCT#06418204)

Read More
December 4, 2024 in Cancer Control / CCDR

S2013

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (NCT# 04871542)
Read More
August 12, 2024 in Cancer Control / CCDR

EAQ222CD

Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients
Read More
March 26, 2024 in Cancer Control / CCDR

CC011

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial (NCT05896189)
Read More
See All

Gastrointestinal

July 14, 2025 in Gastrointestinal (GI)

LUCERNA 8951-CL-0305

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction…
Read More
February 19, 2025 in Gastrointestinal (GI)

S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

Read More
October 9, 2024 in Gastrointestinal (GI)

S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) (NCT 06203600)
Read More
May 29, 2024 in Gastrointestinal (GI)

A022106

Phase II/III second-line NABPLAGEM vs. nab-paclitaxel/gemcitabine in BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM)
Read More
March 11, 2024 in Gastrointestinal (GI)

A022004

Randomized trial of consolidation targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer
Read More
May 31, 2023 in Gastrointestinal (GI)

A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASUR)
Read More
See All

Genitourinary

October 20, 2025 in Genitourinary (GU)

S2427: Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT) (NCT# 07061964)

Read More
July 28, 2025 in Genitourinary (GU)

A032201: Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-risk renal cell carcinoma – STRIKE (NCT06661720)

Read More
June 23, 2025 in Genitourinary (GU)

A032102: PREcision DIagnostics in prostate Cancer Treatment (PREDICT)

Read More
April 7, 2025 in Genitourinary (GU)

S2312: A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate-resistant Prostate Cancer (MCrPC), Stratified by Aggressive Variant Signature (NCT# 06470243)

Read More
August 13, 2024 in Genitourinary (GU)

GU013

The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer
Read More
May 20, 2024 in Genitourinary (GU)

MK5684

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and…
Read More
See All

Gynecology

October 27, 2025 in Gynecology

GY036: A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (NCT#06580314)

Read More
October 8, 2025 in Gynecology

GY032: A PHASE II STUDY OF TAILORED ADJUVANT THERAPY IN POLE-MUTATED AND p53-WILDTYPE/NSMP EARLY-STAGE ENDOMETRIAL CANCER (RAINBO BLUE & TAPER)

Read More
July 23, 2025 in Gynecology

GOG3115/M25-231

A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Read More
July 7, 2025 in Gynecology

GY025: Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Read More
August 29, 2024 in Gynecology

GOG3104/ASCENT-GYN-01

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Read More
July 17, 2024 in Gynecology

EAY191-N5

A Randomized Trial of Neratinib, a Pan-ErbB Inhibitor alone or in combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and other Solid Tumors A ComboMATCH Treatment…
Read More
See All

Head and Neck

August 13, 2025 in Head and Neck

A092205: Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease (NCT06589804)

Read More
April 8, 2025 in Head and Neck

EA3231, A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

Read More
May 22, 2024 in Head and Neck

EA3211

Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma (NCT04671667)
Read More
March 27, 2023 in Head and Neck

HN010

A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer (NCT05408845)
Read More
June 30, 2022 in Head and Neck

EA3191

EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Read More
June 30, 2022 in Head and Neck

EA3161

EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Read More
See All

Hematology

October 1, 2025 in Hematology

MM1OA-S03: A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A myeloMATCH Substudy

Read More
May 21, 2025 in Hematology

BELLWAVE-011

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)
Read More
April 8, 2025 in Hematology

MM1YA-S01: A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial

Read More
March 10, 2025 in Hematology

MM1YA-CTG01: A measurable residual disease (MRD) focused, phase II study of venetoclax plus chemotherapy for newly diagnosed younger patients with intermediate risk Acute Myeloid Leukemia (AML): A Tier 1 myeloMATCH Clinical Trial

Read More
February 26, 2025 in Hematology

MM1OA-EA02: A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial (NCT06317649)

Read More
February 26, 2025 in Hematology

MYELOMATCH: Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials (NCT # 05564390)

Read More
See All

Lung

October 20, 2025 in Lung

S2409, PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) (NCT# 06769126)

Read More
October 1, 2025 in Lung

S2414: A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non-Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT) (NCT06498635)

Read More
October 1, 2025 in Lung

BR.38: Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer – A Randomized Phase III Trial (NCT #06686771)

Read More
August 26, 2025 in Lung

EA5231: A Randomized Phase III Trial of Checkpoint blockade in Lung cancEr patients in the Adjuvant setting based on pathologic Response following neoadjuvant therapy (CLEAR) (NCT06732401)

Read More
August 21, 2025 in Lung

BE6A Lung-02 (C5751003)

AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS…
Read More
June 23, 2025 in Lung

S1800E: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Read More
See All

Melanoma

August 16, 2022 in Melanoma

A091903

A091903: A Randomized Phase II Trial of Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Mucosal Melanoma (NCT05111574)
Read More
June 30, 2022 in Melanoma

EA6141

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Read More
See All

MNCCTN

December 20, 2023 in MNCCTN

MNCCTN031

T-DM1-A Study of the Natural History of Ado-trastuzumab emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
Read More
August 31, 2023 in MNCCTN

MNCCTN013

Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors
Read More
See All

Sarcoma

See All

Other Sites

June 20, 2024 in Other Sites

ES2021-05 – Contact MMCORC for more information

Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer
Read More
October 30, 2023 in Other Sites

EAY191-E4

ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors (NCT #05554341)
Read More
June 14, 2023 in Other Sites

EAY191-S3

Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors
Read More
May 10, 2023 in Other Sites

EAY191

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Read More
July 11, 2022 in Other Sites

S2012

S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Read More
July 11, 2022 in Other Sites

S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Read More
See All